Dr. Rini Discusses the Findings of IMmotion151 in RCC

Brian I. Rini, MD
Published: Monday, Jun 11, 2018



Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma (RCC).

IMmotion151 is a phase III, randomized study of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with untreated PD-L1–positive metastatic RCC. Findings thus far have shown a reduction in the risk of progression or death by 26% compared with sunitinib (Sutent). Additionally, the median progression-free survival by investigator assessment for PD-L1 expressers on ≥1% of immune cells (n = 362) was 11.2 months (95% CI, 8.9-15.0) with atezolizumab and bevacizumab compared with 7.7 months (95% CI, 6.8-9.7) with sunitinib (HR, 0.74; 95% CI, 0.57-0.96; P = .0217).

At the 2018 ASCO Annual Meeting, Rini presented the patient-reported outcomes. Reports concluded that while on atezolizumab plus bevacizumab, patients maintained a good quality of life with minimum symptom interference versus sunitinib. Patients who received the combination had less symptom severity, and milder toxicities than those who received sunitinib.


Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma (RCC).

IMmotion151 is a phase III, randomized study of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with untreated PD-L1–positive metastatic RCC. Findings thus far have shown a reduction in the risk of progression or death by 26% compared with sunitinib (Sutent). Additionally, the median progression-free survival by investigator assessment for PD-L1 expressers on ≥1% of immune cells (n = 362) was 11.2 months (95% CI, 8.9-15.0) with atezolizumab and bevacizumab compared with 7.7 months (95% CI, 6.8-9.7) with sunitinib (HR, 0.74; 95% CI, 0.57-0.96; P = .0217).

At the 2018 ASCO Annual Meeting, Rini presented the patient-reported outcomes. Reports concluded that while on atezolizumab plus bevacizumab, patients maintained a good quality of life with minimum symptom interference versus sunitinib. Patients who received the combination had less symptom severity, and milder toxicities than those who received sunitinib.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x